Inventor
DIX DANIEL
US28 patents
⚠️ This page may combine multiple inventors who share the name “DIX DANIEL”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
19 patentsUS10464992B2Nov 5, 2019
VEGF antagonist formulations suitable for intravitreal administration
REGENERON PHARMA60 citations99
US10400025B2Sep 3, 2019
VEGF antagonist formulations suitable for intravitreal administration
REGENERON PHARMA54 citations99
US9914763B2Mar 13, 2018
VEGF antagonist formulations suitable for intravitreal administration
REGENERON PHARMA56 citations99
US9340594B2May 17, 2016
VEGF antagonist formulations for intravitreal administration
REGENERON PHARMA73 citations99
US8802107B2Aug 12, 2014
VEGF antagonist formulations for intravitreal administration
REGENERON PHARMA65 citations99
US9511140B2Dec 6, 2016
Stable VEGF antagonist formulations
REGENERON PHARMA62 citations98
US9416167B2Aug 16, 2016
Stable liquid formulations of dimer VEGF antagonists
REGENERON PHARMA62 citations98
US8921316B2Dec 30, 2014
Stable liquid VEGF antagonist formulations
REGENERON PHARMA62 citations98
US7807164B2Oct 5, 2010
Lyophilized VEGF antagonist formulations for intravitreal administration
REGENERON PHARMA83 citations98
US11084865B2Aug 10, 2021
VEGF antagonist formulations suitable for intravitreal administration
REGENERON PHARMA14 citations94
US11066458B2Jul 20, 2021
VEGF antagonist formulations suitable for intravitreal administration
REGENERON PHARMA12 citations94
US10342876B2Jul 9, 2019
Process for reducing subvisible particles in a pharmaceutical formulation
REGENERON PHARMA17 citations92
US11732024B2Aug 22, 2023
VEGF antagonist formulations suitable for intravitreal administration
REGENERON PHARMA2 citations84
US7572893B2Aug 11, 2009
IL-1 antagonist formulations
REGENERON PHARMA11 citations81
US12331099B2Jun 17, 2025
VEGF antagonist formulations suitable for intravitreal administration
REGENERON PHARMA0 citations73
US7655758B2Feb 2, 2010
Stable liquid IL-1 antagonist formulations
REGENERON PHARMA6 citations71
US7365165B2Apr 29, 2008
IL-1 antagonist formulations
REGENERON PHARMA8 citations71
US11071780B2Jul 27, 2021
Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
REGENERON PHARMA0 citations58
US9675692B2Jun 13, 2017
Stabilized formulations containing anti-DLL4 antibodies
REGENERON PHARMA0 citations51